Ariad has been under considerable short selling pressure since 6/14/2010. This has precipitated some distribution as stop loss orders have been triggered by the short sales.
In addition, as you noted, there has been some weakness in the speculative end of the biotech sector and in small caps in general. Good news will reverse the downward trend rather quickly.